Advertisement

Ovarian Cancer pp 261-271 | Cite as

Inhibitory B7 Family Members in Human Ovarian Carcinoma

  • Shuang Wei
  • Tyler Curiel
  • George Coukos
  • Rebecca Liu
  • Weiping Zou
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 622)

Tumors express tumor-associated antigens (TAA), and thus should be the object of immune attack. Nonetheless, spontaneous clearance of established tumors is rare (1, 2). Much work has demonstrated that tumors have numerous strategies either to prevent presentation of TAA or to prevent TAA presentation in the context of T cell costimulatory molecules (3–12).

Thus, it was thought that a lack of TAA-specific immunity was largely a passive process; tumors simply did not present enough TAA, or antigen-presenting cells did not have sufficient stimulatory capacity. On this basis, attempts were made to bolster TAA-specific immunity by using optimal antigen-presenting cells (13–15), by growing TAA-specific effector T cells ex vivo followed by adoptive transfer (3–10, 16), by cytokine/chemokine immunotherapy (1, 17), or by peptide vaccination (18–21). These approaches were met with some success in mouse models of human tumors and showed some early clinical efficacy in human trials, although long-term efficacy remains to be established and logistical problems are considerable (3–12).

Keywords

Ovarian Cancer Renal Cell Carcinoma Treg Cell Human Ovarian Cancer Ovarian Tumor Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Springer 2008

Authors and Affiliations

  • Shuang Wei
  • Tyler Curiel
    • 1
  • George Coukos
    • 2
  • Rebecca Liu
  • Weiping Zou
  1. 1.Department of Internal MedicineTulane University School of MedicineNew Orleans
  2. 2.Center for Research on the Early Detection and Cure of Ovarian CancerUniversity of PennsylvaniaPhiladelphia

Personalised recommendations